Hello
TFC Enters USD-Agreements For Egyptian Women, Palestinian Crafts
Sep 7, 2023
A comparison of the two joining processes shows that friction stir welds are stronger and they are flush with the parent material. They have improved sealing with void-free and leak-proof joints, and they provide tight tolerances due to reduced heat distortion.
Here are some of the details that I believe you will find interesting when comparing the processes.
- Weld performance. The tensile strength performance of friction stir welded aluminium alloys is superior to fusion welding, with joint efficiencies measuring 83% or higher. Data also shows that the performance of friction stir welds in aluminium alloys is superior to that of fusion processes in terms of fatigue. In addition, FSW displays a high degree of repeatability, with low scatter in the data. Experience and extensive testing show that a FSW joint is usually stronger than a fusion weld
- Weld structure. Apart from the performance difference, there are also visual differences between FSW and fusion welds. Viewed from the cross-section, the MIG weld builds up. The filler material has a different chemical composition compared to the parent material. Meanwhile, the FSW weld is in principle flush with the material which is being welded. No filler material is used.
- Corrosion resistance. Corrosion resistance of FSW welds in common 5xxx and 6xxx aluminium alloys is comparable to the parent material and often exceeds that of fusion welds. This is related to a finer microstructure, absence of porosity and no addition of other materials (filler). Tests of friction stir welded 6082 performed by Hydro revealed that, after 1,000 hours of SWAAT testing, neither yield nor ultimate strength were affected. Through the correct control of the FSW parameters, this performance can even be improved. Variation of welding speed and tool rotation can have a positive impact on the corrosion resistance in the weld.
Those are the key points, but friction stir welding provides other benefits, too. One is that you achieve minimal distortion after welding compared to fusion welding. Another is simply the end result, with FSW giving you a nice flat surface with little-to-no need for grinding or brushing.
Lastly, this is a full-to-half automated process that reduces man-hours in the shop for welding and assembly.
Tags
Share
Advertise here, Be the LEADER
Advertise Now
Latest Experts Thoughts
Testing By Ayesha
Ghada Ismail
Founded in 2006 in San Marino, Bioscience Institute has grown into a leading name in regenerative medicine and genomics, with key operations in Europe and the Middle East. The company was the first to establish a private stem cell lab in the GCC, launching a state-of-the-art Cell Factory and Biobank in Dubai.
Known for its strong focus on research and innovation, Bioscience works closely with top universities and reinvests in developing advanced therapies. As it looks to expand further into the Gulf, particularly Saudi Arabia, the company is bringing its expertise in stem cells, personalized medicine, and AI-powered diagnostics to the region.
In this interview, we explore how Bioscience built credibility in a new field, how it views the Saudi market, and what’s next for its growth in the GCC.
You launched the first private stem cell lab in the GCC back in 2013. What was the regional and global landscape for stem cell therapy like at the time, and how did you establish scientific credibility in such an emerging field?
When we began our stem cell cultivation activity in Dubai in 2013, we built a cell factory that was the only one of its kind in the entire Middle East. At the time, there were only about a hundred clinical trials underway, whereas now there are more than 1,600. Back then, there were no authorizations from the FDA or the European Medicines Agency, whereas now such approvals exist. Scientific evidence was limited to a few localized treatments, whereas today systemic physiopathological and pathological conditions are being treated with excellent results. Scientific evidence and our rigorous activity have contributed to building our credibility in the region.
Bioscience has been operating across Europe and the UAE. What draws you to Saudi Arabia now, and how do you view its potential for knowledge transfer and long-term collaboration?
We are very interested in what is happening in KSA and in the opportunity to export our know-how, which began to take shape in 2007 when we started our operations in Italy. For this to happen, it will be necessary to share our experience with a Saudi partner who is suitable in terms of expertise and capabilities.
How would you describe the regulatory and cultural environment in the GCC when it comes to adopting advanced biomedical technologies like stem cell therapy?
The regulatory and cultural environment of the GCC has been open to dialogue and has not taken a prejudiced stance. As a result, it focuses on the substance of proposals, facilitating the introduction of innovative technologies in the region more quickly than in other countries. The GCC regulatory framework is highly flexible and is not influenced by the lobbying of large industries, as is often the case in the USA and Europe.
How is Bioscience leveraging AI to support clinical decision-making and improve patient outcomes, especially as the company expands into more complex markets like Saudi Arabia?
We use AI for our Clinical Decision Support System, which assists our physicians in performing accurate patient assessments and identifying the most suitable therapy by cross-referencing data from numerous biomarkers—something that would otherwise be impossible for a human to achieve.
With digital transformation reshaping patient expectations in Saudi Arabia, how is Bioscience adapting its technology and service models to meet demand for more personalized and tech-enabled care?
We have developed an IT platform that functions as an operating system and can be integrated into the operations of any clinic, enabling the use of the most advanced protocol in the fields of molecular biology, genomics, and regenerative medicine with stem cells and exosomes.
Given Saudi Arabia’s growing investment in biotech and innovation, do you see the Kingdom emerging as a regional R&D hub for regenerative medicine in the coming years?
Saudi Arabia has the potential to become a hub for R&D in regenerative medicine; however, in addition to investments, a supportive environment and incentives should be created for companies with know-how that could be shared.
Testing By Ayesha
Ghada Ismail
Founded in 2006 in San Marino, Bioscience Institute has grown into a leading name in regenerative medicine and genomics, with key operations in Europe and the Middle East. The company was the first to establish a private stem cell lab in the GCC, launching a state-of-the-art Cell Factory and Biobank in Dubai.
Known for its strong focus on research and innovation, Bioscience works closely with top universities and reinvests in developing advanced therapies. As it looks to expand further into the Gulf, particularly Saudi Arabia, the company is bringing its expertise in stem cells, personalized medicine, and AI-powered diagnostics to the region.
In this interview, we explore how Bioscience built credibility in a new field, how it views the Saudi market, and what’s next for its growth in the GCC.
You launched the first private stem cell lab in the GCC back in 2013. What was the regional and global landscape for stem cell therapy like at the time, and how did you establish scientific credibility in such an emerging field?
When we began our stem cell cultivation activity in Dubai in 2013, we built a cell factory that was the only one of its kind in the entire Middle East. At the time, there were only about a hundred clinical trials underway, whereas now there are more than 1,600. Back then, there were no authorizations from the FDA or the European Medicines Agency, whereas now such approvals exist. Scientific evidence was limited to a few localized treatments, whereas today systemic physiopathological and pathological conditions are being treated with excellent results. Scientific evidence and our rigorous activity have contributed to building our credibility in the region.
Bioscience has been operating across Europe and the UAE. What draws you to Saudi Arabia now, and how do you view its potential for knowledge transfer and long-term collaboration?
We are very interested in what is happening in KSA and in the opportunity to export our know-how, which began to take shape in 2007 when we started our operations in Italy. For this to happen, it will be necessary to share our experience with a Saudi partner who is suitable in terms of expertise and capabilities.
How would you describe the regulatory and cultural environment in the GCC when it comes to adopting advanced biomedical technologies like stem cell therapy?
The regulatory and cultural environment of the GCC has been open to dialogue and has not taken a prejudiced stance. As a result, it focuses on the substance of proposals, facilitating the introduction of innovative technologies in the region more quickly than in other countries. The GCC regulatory framework is highly flexible and is not influenced by the lobbying of large industries, as is often the case in the USA and Europe.
How is Bioscience leveraging AI to support clinical decision-making and improve patient outcomes, especially as the company expands into more complex markets like Saudi Arabia?
We use AI for our Clinical Decision Support System, which assists our physicians in performing accurate patient assessments and identifying the most suitable therapy by cross-referencing data from numerous biomarkers—something that would otherwise be impossible for a human to achieve.
With digital transformation reshaping patient expectations in Saudi Arabia, how is Bioscience adapting its technology and service models to meet demand for more personalized and tech-enabled care?
We have developed an IT platform that functions as an operating system and can be integrated into the operations of any clinic, enabling the use of the most advanced protocol in the fields of molecular biology, genomics, and regenerative medicine with stem cells and exosomes.
Given Saudi Arabia’s growing investment in biotech and innovation, do you see the Kingdom emerging as a regional R&D hub for regenerative medicine in the coming years?
Saudi Arabia has the potential to become a hub for R&D in regenerative medicine; however, in addition to investments, a supportive environment and incentives should be created for companies with know-how that could be shared.
Testing By Ayesha
<body>
<h1>Welcome to My Website</h1>
<p>This is a simple HTML page.</p>
<button onclick="alert('Hello!')">Click Me</button>
</body>
Buguard's Founder: We raised $500K in seed round, studying expansion in Saudi Arabia
As organizations across the MEA region increasingly embrace digitalization strategies and rapidly shift toward cloud migration, we will inevitably see an expansion of the threat surface area. The region has already witnessed exponential growth in threats such as DDoS attacks, phishing, and ransomware, resulting in the implementation of strict regulatory compliance measures across many countries and greater awareness around the need for organizations to improve their security postures. This will drive strong demand for security solutions over the next few years until the situation stabilizes.